Skip to main content
OpenTrials

Clinical trial condition

Digestive System Neoplasms

Explore clinical trials studying Digestive System Neoplasms. Study availability and eligibility vary by location and protocol.

14,418 public trials 3,293 recruiting studies
Refine in advanced search Browse all conditions

Digestive System Neoplasms trial results

Completed

Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors

NCT01576666

Conditions
Advanced Pancreatic Adenocarcinoma, Advanced Solid Tumors, Astrocytoma, +35 more
Locations
  • Cedars Sinai Medical Center SC Los Angeles, California, United States
  • University of California San Francisco UCSF (SC) San Francisco, California, United States
  • H. Lee Moffitt Cancer Center & Research Institute Moffitt 4 Tampa, Florida, United States
  • Dana Farber Cancer Institute Dana SC Boston, Massachusetts, United States
View all 23 locations
View Trial Details
Completed

Dose-escalation, and Safety Study of LDE225 and Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer Patients

NCT01487785

Conditions
Adenocarcinoma, Carcinoma, Digestive System Diseases, +10 more
Locations
  • Massachusetts General Hospital Dept. of Mass General Hospital Boston, Massachusetts, United States
  • Memorial Sloan Kettering Cancer Center MSKCC - SC New York, United States
  • University of Utah / Huntsman Cancer Institute Huntsman UT Salt Lake City, Utah, United States
  • Novartis Investigative Site Barcelona, Catalonia, Spain
View Trial Details
Completed

Study of Safety & Efficacy of the Combination of LJM716 & BYL719 in Patients With Previously Treated Esophageal Squamous Cell Carcinoma (ESCC)

NCT01822613

Conditions
Carcinoma, Carcinoma, Squamous Cell, Digestive System Diseases, +12 more
Locations
  • University of Chicago Medical Center Dept of Onc Chicago, Illinois, United States
  • Karmanos Cancer Institute Dept of Onc Detroit, Michigan, United States
  • University of Texas/MD Anderson Cancer Center Gastrointestinal Med. Oncology Houston, Texas, United States
  • Novartis Investigative Site Brussels, Belgium
View all 13 locations
View Trial Details
Completed

A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer

NCT02082210

Conditions
Adenocarcinoma, Advanced Cancer, Bronchial Neoplasms, +31 more
Locations
  • Massachusetts General Hospital Boston, Massachusetts, United States
  • Dana Farber Cancer Institute Boston, Massachusetts, United States
  • Memorial Sloan Kettering Cancer Center New York, United States
  • Tennessee Oncology PLLC Nashville, Tennessee, United States
View Trial Details
Completed

Gastric Cancer Precursor Lesions (GCPL) Study

NCT03188406

Conditions
Digestive System Diseases, Digestive System Neoplasms, Gastric Cancer, +10 more
Locations
  • Universidad de Concepción Concepción, Chile
  • Hospital de Curanilahue Curanilahue, Chile
  • Hospital Intercultural Nueva Imperial, Chile
  • Hospital de Puerto Montt Port Montt, Chile
View Trial Details
Completed

Study of Safety and Tolerability of PDR001 in Combination With Sorafenib and to Identify the Maximum Tolerated Dose and/or Phase 2 Dose for This Combination in Advanced Hepatocellular Patients

NCT02988440

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +9 more
Locations
  • Karmanos Cancer Institute Detroit, Michigan, United States
  • Novartis Investigative Site Montreal, Quebec, Canada
  • Novartis Investigative Site Essen, Germany
  • Novartis Investigative Site Hong Kong
View Trial Details
Completed

Phase I Study LJM716 Combined With Trastuzumab in Patients With HER2 Overexpressing Metastatic Breast or Gastric Cancer

NCT01602406

Conditions
Advanced HER2-positive Breast Cancer or Gastric Cancer, Digestive System Diseases, Digestive System Neoplasms, +6 more
Locations
  • Novartis Investigative Site Boston, Massachusetts, United States
  • Novartis Investigative Site Chapel Hill, North Carolina, United States
  • Novartis Investigative Site Philadelphia, Pennsylvania, United States
  • Novartis Investigative Site Wilrijk, Belgium
View Trial Details

Related conditions